Shots:
- The US FDA has approved FoundationOne CDx to be used as a CDx for Alunbrig (brigatinib) which is approved for the treatment of adult patients with ALK+ mNSCLC as detected by an FDA-approved test
- In Sept’20, Foundation Medicine and Takeda collaborated to develop CDx for therapies in its late-stage lung portfolio
- FoundationOne CDx is the only FDA-approved tissue-based CGP test and is now able to detect ALK+ mNSCLC and identify patients who may be appropriate for treatment with Alunbrig which is approved as a 1L or later-line therapy
Click here to read full press release/ article | Ref: Business Wire | Image: WRAL TechWire
The post The US FDA Approves FoundationOne CDx for Alunbrig (brigatinib) in Patients with ALK+ NSCLC first appeared on PharmaShots.
